See more : Root, Inc. (ROOT) Income Statement Analysis – Financial Results
Complete financial analysis of Cullinan Oncology, Inc. (CGEM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cullinan Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Qinqin Foodstuffs Group (Cayman) Company Limited (QQFSF) Income Statement Analysis – Financial Results
- Advance Create Co., Ltd. (8798.T) Income Statement Analysis – Financial Results
- Rio2 Limited (RIOFF) Income Statement Analysis – Financial Results
- Dampskibsselskabet Norden A/S (DPBSF) Income Statement Analysis – Financial Results
- Southeast Cement Corporation (1110.TW) Income Statement Analysis – Financial Results
Cullinan Oncology, Inc. (CGEM)
About Cullinan Oncology, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 18.94M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 310.00K | 93.00K | 53.00K | 62.00K | 70.00K | 43.00K |
| Gross Profit | -310.00K | -93.00K | 18.89M | -62.00K | -70.00K | -43.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.72% | 0.00% | 0.00% | 0.00% |
| Research & Development | 148.16M | 91.95M | 57.75M | 43.21M | 16.79M | 9.58M |
| General & Administrative | 42.49M | 40.19M | 29.15M | 17.12M | 5.48M | 5.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.49M | 40.19M | 29.15M | 17.12M | 5.48M | 5.00M |
| Other Expenses | 440.00K | 57.00K | -8.00K | -11.00K | -4.00K | 0.00 |
| Operating Expenses | 191.09M | 132.14M | 86.90M | 60.34M | 22.27M | 14.59M |
| Cost & Expenses | 191.09M | 132.14M | 86.90M | 60.34M | 22.27M | 14.59M |
| Interest Income | 21.63M | 6.61M | 477.00K | 888.00K | 620.00K | 397.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 310.00K | 93.00K | 53.00K | 62.00K | 70.00K | 43.00K |
| EBITDA | -190.34M | 151.41M | -67.90M | -60.27M | -22.20M | -14.54M |
| EBITDA Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% | 0.00% |
| Operating Income | -191.09M | 144.65M | -67.95M | -60.34M | -22.27M | -14.59M |
| Operating Income Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 21.87M | 6.67M | 469.00K | 877.00K | 616.00K | 397.00K |
| Income Before Tax | -169.22M | 151.32M | -67.49M | -59.46M | -21.65M | -14.19M |
| Income Before Tax Ratio | 0.00% | 0.00% | -356.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -14.12M | 42.12M | -2.45M | -8.61M | -1.62M | 397.00K |
| Net Income | -153.16M | 111.21M | -65.04M | -50.85M | -20.04M | -14.19M |
| Net Income Ratio | 0.00% | 0.00% | -343.35% | 0.00% | 0.00% | 0.00% |
| EPS | -3.69 | 2.46 | -1.47 | -1.17 | -0.46 | -1.24 |
| EPS Diluted | -3.69 | 2.38 | -1.47 | -1.17 | -0.46 | -1.24 |
| Weighted Avg Shares Out | 41.51M | 45.16M | 44.29M | 43.52M | 43.52M | 11.45M |
| Weighted Avg Shares Out (Dil) | 41.55M | 46.64M | 44.29M | 43.52M | 43.52M | 11.45M |
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Cullinan Oncology to Participate in Upcoming Investor Conferences
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Source: https://incomestatements.info
Category: Stock Reports